Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse

Investigational New Drugs

Volumn 20, Issue 4, 2002, Pages 395-406

  Berger, Mark S ^a,b   Leopold, Lance H ^a,b   Dowell, James A ^a,b   Korth Bradley, Joan M ^a,b   Sherman, Matthew L ^a,b  

^a PFIZER INC   (United States)

^b NONE   (United States)

Author keywords

AML; Antibody targeted chemotherapy; Calicheamicin; Gemtuzumab ozogamicin; Relapsed leukemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ASCITES; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HYPERBILIRUBINEMIA; IMMUNOGENICITY; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SEPSIS; SIDE EFFECT;

AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LICENSURE; MIDDLE AGED; RECURRENCE; SURVIVAL RATE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036829583     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020658028082     Document Type: Review

References (39)

1. Löwenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Eng J Med 341:1051-1062, 1999
2. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, Buchner T: Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17:3569-3576, 1999
3. Brincker H: Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 69:5-11, 1985
4. Cripe LD: Adult acute leukemia. Curr Prob Cancer 21:7-64, 1997
5. Bolam S, Hambin T: Colony stimulating factors in the treatment of older patients with acute myelogenous leukaemia. Drugs Aging 15:451-460, 1999
6. Bishop JF: The treatment of adult acute myeloid leukemia. Semin Oncol 24:57-69, 1997
7. Kantarjian HM, Estey EH, Keating MA: New chemotherapeutic agents in acute myeloid leukemia. Leukemia 10:S4-S6, 1996
8. Angelov L, Brandwein JM, Baker MA, Scott JG, Sutton DM, Keating A: Results of therapy for acute myeloid leukemia in first relapse. Leuk Lymphoma 6:15-24, 1991
9. Davis CL, Rohatiner AZ, Lim J, Whelan JS, Oza AM, Amess J, Love S, Stead E, Lister TA: The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 83:404-411, 1993.
10. Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H, Rigal-Huguet F, Facon T, Dufour P, Ifrah N: Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. J Clin Oncol 7:45-49, 1989
11. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T: Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 4:184-188, 1990
12. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ: Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7:1071-1080, 1989
13. Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W: Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison. Leukemia 12:1049-1055, 1998
14. Letendre L, Kiely JM, Hoagland HC. Reinduction chemotherapy for acute nonlymphocytic leukemia. Mayo Clin Proc 59:618-621, 1984
15. MacCallum PK, Davis CL, Rohatiner AZ, Lim J, Gupta RK, Whelan JS, Price CG, Evans ML, Amess JA, Leahy M, Johnson PWM, Oza AM, Lister TA: Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia 7:1496-1499, 1993
16. Rees JK, Gray RG, Swirsky D, Hayhoe FG: Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 2:1236-1241, 1986
17. Steinberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN: Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine. Cancer 88:2037-2041, 2000
18. Stockerl-Goldstein KE, Blume KG: Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Forman SJ, Blume KG, Thomas ED (eds): Hematopoietic Cell Transplantation, vol 2. Blackwell Science, Boston, 1999, pp 823-834
19. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou H-R, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I: Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibodycalicheamicin conjugate for the treatment of acute myeloid leukemia. Bioconjug Chem 13:47-58, 2002
20. Legrand O, Perrot J-Y, Baudard M, Cordier A, Lautier R, Simonin G, Zittoun R, Casadevall N, Marie J-P: The immunophenotype of 177 adults with acute myeloid leukemia: Proposal of a prognostic score Blood 96:870-877, 2000
21. van der Velden VHJ, te Marvelde JG, Hoogeveen PG, Bernstein I, Houtsmuller AB, Berger MS, van Dongen JJM: Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97:3197-3204, 2001
22. Dowell JA, King SP, Liu H, Berger MS, Korth Bradley JM: Assessment of the pharmacokinetics of gemtuzumab ozogamicin in pediatric patients with relapsed acute myelogenous leukemia (Abstract). Pharmacother 20:1256, 2000
23. Dowell JA, King SP, Liu H, Berger MS, Korth-Bradley JM: A population pharmacokinetic analysis of gemtuzumab ozogamicin: A new antibody chemo-therapeutic agent (Abstract). Clin Pharm Ther 67:138, 2000
24. Korth-Bradley JM, Dowell JA, King SP, Liu H, Berger MS: Investigation of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacother 21:1175-1180, 2001
25. Wang CP, Lim HK, Hultin T, Hamann P, Beyer CF, Ma S, Chan K, King SP, Scatina A: Characterization of in vitro metabolism of two postulated hydrolytic products of CMA-676. NAC-γ-calicheamicin DMH and NAC-γ-calicheamicin DMH AcBUT in human liver microsomes and cytosol and NAC-γ-calicheamicin DMA in HL-60 promyelocytic leukemia cells (Abstract). ISSX Proceedings 15:111, 1999
26. Sievers EL, Appelbaum FR, Spielberger RT, Forman S, Flowers D, Smith F, Shannon-Dorcy K, Berger M, Bernstein I: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678-3684, 1999
27. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJM, Bernstein ID, Appelbaum F: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254, 2001
28. Sievers EL, Arceci R, Franklin J, Lange B, Shannon K, Smith F, Beger MS, Eten C, Auen M: Preliminary report of an ascending dose study of gemtuzumab ozogamicin (Mylotarg® CMA-676) in pediatric patients with acute myeloid leukemia (Abstract). Blood 96:217b, 2000
29. Thalhammer F, Geissler K, Jager U, Kyrle PA, Pabinger I, Mitterbauer M, Gisslinger H, Knobl P, Laczika K, Schneider B, Haas OA, Lechner K: Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single-center study. Ann Hematol 72:216-222, 1996
30. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P, Trancy J, Assouline D, Fiere D: Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 13:11-18, 1995
31. Vignetti M, Orsini E, Petti MC, Moleti ML, Andrizzi C, Pinto RM, Amadori S, Meloni G: Probability of long-term diseasefree survival for acute myeloid leukemia patients after first relapse: A single-centre experience. Ann Oncol 7:933-938, 1996
32. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L, Leoni F, Martelli FM, Di Raimondo, F, Porcellini A, de Riu L, Nosari AM, Cimino R, Damasio E, Miraglia E, Fioritoni G, Ricciuti F, Carotenuto M, Longinotti M, Defazio D, Fazi P, MandelIi F: Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leukemia 7:196-199, 1993
33. Vogler WR, McCarley DL, Stagg M, Bartolucci AA, Moore J, Martelo O, Omura GA: A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 8:1847-1853, 1994
34. Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E: Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 13:1214-1220, 1999
35. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, Furusawa S, Imai K, Takemoto Y, Miura Y, Teshima H, Hamajima N: A double-blind controlled study of granulocyte colonystimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 83:2086-2092, 1994
36. Winkler U, Jensen, M, Manzke O, Schultz H, Diehl V, Engert A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217-2224, 1999
37. Sievers EL, Larson RA, Estey E, Stadtmauer E, Castaigne S, Berger MS, Leopold LH, Appelbaum FR: Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg® CMA-676): Relationship to hematopoietic stem cell transplantation (abstract). Blood 96:206b, 2000
38. Neumeister P, Eibl M, Zinke-Cerwenka W, Scarpatetti M, Linkesch W: Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann Hematol 80:119-120, 2001
39. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid DE, Estey EH: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venocclusive disease in patiens who have not received stem cell transplantation. Cancer 92:406-413, 2001